Sartorius has signed an agreement to acquire parts of Danaher’s Life Science portfolio for approximately $750 million.   Danaher is selling these businesses as a step towards obtaining regulatory approval for its pending acquisition of the GE Biopharma business. The closing of the Sartorius agreement is conditioned upon Danaher’s closing the GE deal, which remains subject to approvals from various regulatory authorities.   Thomas P. Joyce, Jr., president and chief executive officer, said, ...